USPTO Grants Patent for Bis-biguanide Compounds in Cancer Management

ChangeBridge: Patent Grants - Therapeutics (A61P)

Published March 24th, 2026

Detected March 24th, 2026

Summary

The USPTO has granted a patent (US12582618B2) to Emory University for bis-biguanide compounds and pharmaceutical compositions for managing cancer, particularly lung cancer. The patent covers methods of treatment and related compositions, with an effective grant date of March 24, 2026.

View original document View source feed page

What changed

The United States Patent and Trademark Office (USPTO) has granted patent US12582618B2 to Emory University. This patent covers methods of managing cancer, specifically lung cancer and small cell lung cancer, using bis-biguanide compounds such as alexidine and pharmaceutical compositions containing them. The patent's abstract details specific embodiments related to treating human subjects diagnosed with these forms of cancer.

This patent grant is primarily an intellectual property matter and does not impose direct regulatory obligations on pharmaceutical companies or healthcare providers. However, it signifies exclusive rights for Emory University concerning the patented compounds and methods, which may impact future drug development, licensing, and commercialization efforts in the oncology space. Companies operating in this therapeutic area should be aware of this granted patent and its potential implications for their research and development pipelines.

Source document (simplified)

← USPTO Patent Grants

Bis-biguanide compounds, pharmaceutical compositions and uses in managing cancer

Grant US12582618B2 Kind: B2 Mar 24, 2026

Assignee

Emory University

Inventors

Adam Marcus, Jessica Konen, Rachel Commander, Jamie Arnst, Thota Ganesh

Abstract

This disclosure relates to methods of managing cancer using bis-biguanide compounds, such as alexidine, and pharmaceutical compositions comprising the same. In certain embodiments, this disclosure relates to methods of treating lung cancer comprising administering an effective amount of a bis-biguanide compound to a subject in need thereof. In certain embodiments, this disclosure relates to methods of treating small cell lung cancer comprising administering an effective amount of a bis-biguanide compound to a subject in need thereof. In certain embodiments, the subject is diagnosed with a lung cancer. In certain embodiments, the subject is diagnosed with small cell lung cancer. In certain embodiments, the subject is a human subject.